kirsty (previously kixelle)
biosimilar collaborations ireland limited - insúlín aspart - sykursýki - lyf notuð við sykursýki - kirsty is indicated for treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.
byooviz
samsung bioepis nl b.v. - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - augnlækningar - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).
kapruvia
vifor fresenius medical care renal pharma france - difelikefalin - pruritus - Öll önnur lækningavörur - kapruvia is indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult patients on haemodialysis (see section 5.
ximluci
stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - augnlækningar - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).
ranivisio
midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - augnlækningar - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).
sotyktu
bristol-myers squibb pharma eeig - deucravacitinib - psoriasis - Ónæmisbælandi lyf - treatment of moderate-to-severe plaque psoriasis in adults.
montelukast ratiopharm (montelukast teva) tuggutafla 4 mg
teva sweden ab - montelukastum natríum - tuggutafla - 4 mg
montelukast ratiopharm (montelukast teva) tuggutafla 5 mg
teva sweden ab - montelukastum natríum - tuggutafla - 5 mg
singulair tuggutafla 4 mg
n.v. organon* - montelukastum natríum - tuggutafla - 4 mg
herwenda
sandoz gmbh - trastuzúmab - breast neoplasms; stomach neoplasms - Æxlishemjandi lyf - treatment of metastatic and early breast cancer and metastatic gastric cancer (mgc).